Laurus Labs Limited (LAURUSLABS.NS)
INR 628.05
(0.18%)
INR 628.05
(0.18%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 50.01 Billion INR | -16.55% |
| 2022 | 60.4 Billion INR | 23.57% |
| 2021 | 48.88 Billion INR | 3.5% |
| 2020 | 47.23 Billion INR | 71.22% |
| 2019 | 27.58 Billion INR | 23.15% |
| 2018 | 22.4 Billion INR | 12.17% |
| 2017 | 19.97 Billion INR | 7.06% |
| 2016 | 18.65 Billion INR | 6.26% |
| 2015 | 17.55 Billion INR | 33.57% |
| 2014 | 13.14 Billion INR | 13.67% |
| 2013 | 11.56 Billion INR | 60.92% |
| 2012 | 7.18 Billion INR | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 11.94 Billion INR | -17.0% |
| 2024 Q2 | 12.23 Billion INR | 2.41% |
| 2023 Q4 | 14.39 Billion INR | 20.48% |
| 2023 FY | 50.4 Billion INR | -16.55% |
| 2023 Q1 | 11.81 Billion INR | -14.42% |
| 2023 Q2 | 12.24 Billion INR | 3.61% |
| 2023 Q3 | 11.94 Billion INR | -2.41% |
| 2022 Q4 | 13.8 Billion INR | -10.61% |
| 2022 Q1 | 15.38 Billion INR | 11.7% |
| 2022 Q2 | 15.75 Billion INR | 2.4% |
| 2022 FY | 60.4 Billion INR | 23.57% |
| 2022 Q3 | 15.44 Billion INR | -1.97% |
| 2021 Q3 | 10.28 Billion INR | -14.52% |
| 2021 Q2 | 12.03 Billion INR | -5.87% |
| 2021 FY | 48.88 Billion INR | 3.5% |
| 2021 Q1 | 12.78 Billion INR | -3.26% |
| 2021 Q4 | 13.77 Billion INR | 33.93% |
| 2020 Q3 | 12.88 Billion INR | 13.13% |
| 2020 FY | 47.23 Billion INR | 71.22% |
| 2020 Q1 | 9.74 Billion INR | 27.19% |
| 2020 Q4 | 13.21 Billion INR | 2.58% |
| 2020 Q2 | 11.38 Billion INR | 16.89% |
| 2019 Q1 | 5.5 Billion INR | -5.62% |
| 2019 FY | 27.58 Billion INR | 23.15% |
| 2019 Q4 | 7.66 Billion INR | 4.99% |
| 2019 Q3 | 7.29 Billion INR | 2.41% |
| 2019 Q2 | 7.12 Billion INR | 29.4% |
| 2018 Q1 | 5.39 Billion INR | -3.79% |
| 2018 Q4 | 5.83 Billion INR | 10.18% |
| 2018 FY | 22.4 Billion INR | 12.17% |
| 2018 Q3 | 5.29 Billion INR | -10.0% |
| 2018 Q2 | 5.88 Billion INR | 9.14% |
| 2017 Q1 | 4.78 Billion INR | 1.19% |
| 2017 FY | 19.97 Billion INR | 7.06% |
| 2017 Q2 | 5.38 Billion INR | 12.59% |
| 2017 Q3 | 4.78 Billion INR | -11.08% |
| 2017 Q4 | 5.6 Billion INR | 16.98% |
| 2016 Q4 | 4.72 Billion INR | -6.5% |
| 2016 Q1 | 4.09 Billion INR | 0.0% |
| 2016 FY | 18.65 Billion INR | 6.26% |
| 2016 Q3 | 5.05 Billion INR | -2.1% |
| 2016 Q2 | 5.16 Billion INR | 26.05% |
| 2015 FY | 17.55 Billion INR | 33.57% |
| 2014 FY | 13.14 Billion INR | 13.67% |
| 2013 FY | 11.56 Billion INR | 60.92% |
| 2012 FY | 7.18 Billion INR | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Hester Biosciences Limited | 3.04 Billion INR | -1542.379% |
| Albert David Limited | 3.62 Billion INR | -1279.953% |
| Alembic Limited | 1.57 Billion INR | -3076.042% |
| Alkem Laboratories Limited | 126.67 Billion INR | 60.515% |
| Alembic Pharmaceuticals Limited | 61.12 Billion INR | 18.166% |
| Bafna Pharmaceuticals Limited | 1.52 Billion INR | -3180.607% |
| Bajaj HealthCare Limited | 4.73 Billion INR | -956.53% |
| FDC Limited | 19.42 Billion INR | -157.434% |
| Glenmark Life Sciences Limited | 22.83 Billion INR | -119.068% |
| Gufic Biosciences Limited | 8.06 Billion INR | -520.059% |
| Hikal Limited | 17.84 Billion INR | -180.276% |
| Ind-Swift Laboratories Limited | 12.8 Billion INR | -290.491% |
| Ind-Swift Limited | 5.02 Billion INR | -895.446% |
| Innova Captab Limited | 10.81 Billion INR | -362.571% |
| Jagsonpal Pharmaceuticals Limited | 2.08 Billion INR | -2296.623% |
| Jubilant Pharmova Limited | 67.02 Billion INR | 25.379% |
| Kilitch Drugs (India) Limited | 1.54 Billion INR | -3140.085% |
| Lincoln Pharmaceuticals Limited | 5.8 Billion INR | -761.563% |
| Lupin Limited | 196.56 Billion INR | 74.554% |
| Mangalam Drugs & Organics Limited | 3.67 Billion INR | -1261.576% |
| Medico Remedies Limited | 1.44 Billion INR | -3351.405% |
| Morepen Laboratories Limited | 17.01 Billion INR | -193.895% |
| Nectar Lifesciences Limited | 16.84 Billion INR | -196.918% |
| Orchid Pharma Limited | 8.19 Billion INR | -510.446% |
| Procter & Gamble Health Limited | 11.51 Billion INR | -334.463% |
| RPG Life Sciences Limited | 5.82 Billion INR | -759.342% |
| Solara Active Pharma Sciences Limited | 12.38 Billion INR | -303.895% |
| Sun Pharmaceutical Industries Limited | 484.96 Billion INR | 89.686% |
| Suven Pharmaceuticals Limited | 10.51 Billion INR | -375.749% |
| Themis Medicare Limited | 3.81 Billion INR | -1210.192% |
| Unichem Laboratories Limited | 16.57 Billion INR | -201.783% |
| Vaishali Pharma Limited | 862.79 Million INR | -5697.192% |
| Venus Remedies Limited | 5.91 Billion INR | -745.685% |
| Wanbury Limited | 5.75 Billion INR | -768.896% |
| Windlas Biotech Limited | 6.3 Billion INR | -692.734% |
| ZIM Laboratories Limited | 3.67 Billion INR | -1260.971% |
| Ipca Laboratories Limited | 77.05 Billion INR | 35.091% |
| Aarti Drugs Limited | 25.28 Billion INR | -97.811% |
| Aarti Pharmalabs Limited | 18.15 Billion INR | -175.505% |
| Biofil Chemicals and Pharmaceuticals Limited | 400.35 Million INR | -12393.475% |
| Brooks Laboratories Limited | 794.86 Million INR | -6192.673% |
| Eris Lifesciences Limited | 20.09 Billion INR | -148.952% |
| IOL Chemicals and Pharmaceuticals Limited | 21.32 Billion INR | -134.519% |
| Sigachi Industries Limited | 3.98 Billion INR | -1153.722% |
| Sakar Healthcare Limited | 1.54 Billion INR | -3144.397% |
| Aurobindo Pharma Limited | 290.01 Billion INR | 82.754% |
| Divi's Laboratories Limited | 78.45 Billion INR | 36.242% |
| AstraZeneca Pharma India Limited | 12.95 Billion INR | -286.081% |
| Mankind Pharma Limited | 103.34 Billion INR | 51.602% |
| Sequent Scientific Limited | 13.69 Billion INR | -265.167% |
| Neuland Laboratories Limited | 15.58 Billion INR | -220.92% |
| J. B. Chemicals & Pharmaceuticals Limited | 34.47 Billion INR | -45.078% |
| Glenmark Pharmaceuticals Limited | 118.13 Billion INR | 57.659% |
| Zydus Lifesciences Limited | 190.21 Billion INR | 73.704% |
| Amrutanjan Health Care Limited | 4.21 Billion INR | -1087.426% |
| Wockhardt Limited | 27.89 Billion INR | -79.34% |
| Bal Pharma Limited | 3.39 Billion INR | -1374.502% |
| Dr. Reddy's Laboratories Limited | 279.16 Billion INR | 82.083% |
| Bliss GVS Pharma Limited | 7.7 Billion INR | -549.378% |
| Par Drugs and Chemicals Limited | 956.4 Million INR | -5129.798% |
| Caplin Point Laboratories Limited | 16.76 Billion INR | -198.298% |
| Shilpa Medicare Limited | 11.53 Billion INR | -333.767% |
| Valiant Laboratories Limited | 1.82 Billion INR | -2647.378% |
| Ajanta Pharma Limited | 42.08 Billion INR | -18.844% |
| Aarey Drugs & Pharmaceuticals Limited | 3.95 Billion INR | -1164.301% |
| Granules India Limited | 45.06 Billion INR | -10.994% |
| Medicamen Biotech Limited | 1.79 Billion INR | -2689.53% |
| Syncom Formulations (India) Limited | 2.59 Billion INR | -1829.379% |
| Piramal Enterprises Limited | 60.33 Billion INR | 17.103% |
| Torrent Pharmaceuticals Limited | 106.05 Billion INR | 52.837% |
| NATCO Pharma Limited | 40.02 Billion INR | -24.983% |
| Suven Life Sciences Limited | 116.92 Million INR | -42676.386% |
| Krebs Biochemicals & Industries Limited | 504.21 Million INR | -9819.975% |
| Strides Pharma Science Limited | 40.51 Billion INR | -23.467% |
| Indoco Remedies Limited | 18.17 Billion INR | -175.234% |
| Alpa Laboratories Limited | 1.08 Billion INR | -4499.822% |
| Lasa Supergenerics Limited | 1.04 Billion INR | -4693.981% |
| Sun Pharma Advanced Research Company Limited | 755.45 Million INR | -6520.928% |